Miranda Schmalfuhs’ Post

🚨Our June issue is LIVE🚨 Our annual #Pharma50 issue is BIGGER THAN EVER🔷Mark Cuban speaks about #drugpricing, transparency, and Mark Cuban Cost Plus Drug Company, PBC🔷The 24th listing of ur top 50 #pharma companies🔷How we should respond to the changing #healthcare system🔷and so much more, right here ➡️ https://lnkd.in/em4irY_R

Let's talk about disrupting the status quo in the prescription drug pricing industry. Forward-thinking players are shaking up how middlemen operate, and it’s encouraging to see this shift across the board. Marc Cuban, for example, is bypassing wholesalers and taking direct control. Innovative PBMs, like Abarca, are gaining traction with major players like Blue Shield of California So what does this all mean for the consumer? Our CEO, Umar Afridi, will take the stage at Asembia on Tuesday, April 30 at 1:00 PM to tackle this complex topic. Stop by his panel, “From Opaque to Transparent: Transforming the Way We Pay For Drugs,” and let us know what you think in the comments below. #asembia24 #DigitalHealth #HealthcareInnovation #ConsumerHealthcare #HealthcareTechnology #Healthtech #pharma #pharmacy

For decades, health plans and PBMs railed against drug company pricing and margins. Now, the latest verticalization move in the industry has them buying down (or is it up?) the food chain. If you can't beat 'em, join 'em? Looking forward to see who moves next.   https://lnkd.in/gKuhWSrf   #PBM #DrugBenefits #Pharmacy #ManagedCarePharmacy #Formulary #HealthPlans #Biosimilars #Pharma #HealthCareBusiness #5ForcesofHCT #HCTVerticalization

Discover the Latest Regulatory Insights! 📈📘 Stay informed with the May 2024 edition of the Swissmedic Journal, your authoritative source for therapeutic product regulations in Switzerland. This month’s issue is packed with essential updates and expert analyses that are crucial for healthcare professionals and industry stakeholders. 🔍 Inside This Edition: - Updates on new drug regimens and market regulations - An index of medicinal products with new or modified indications - Critical information on authorizations and withdrawals - Don’t miss out on the knowledge that could shape your strategic decisions! #SwissmedicJournal #HealthcareRegulation #PharmaceuticalInsights

We all need trust in the medicines we take to improve our health. This was huge motivator in the European Medicines Agency's (EMA) giant leap forward with Policy 70, setting a new standard for transparency in the medical field. Our blog breaks down everything you need to know about this groundbreaking policy. From enhancing public health to meeting the growing demand for trust in the pharmaceutical and regulatory landscape, we've got you covered. Read more ⬇️ #emapolicy70 #transparency #healthcareinnovation

We all want trust in the medicines we take to improve ours and our families' health. This was huge motivator in the European Medicines Agency's (EMA) giant leap forward with Policy 70, setting a new standard for transparency in the medical field. Our blog breaks down everything you need to know about this groundbreaking policy. From enhancing public health to meeting the growing demand for trust in the pharmaceutical and regulatory landscape, we've got you covered. Read more ⬇️ #emapolicy70 #transparency #healthcareinnovation

We all want trust in the medicines we take to improve ours and our families' health. This was huge motivator in the European Medicines Agency's (EMA) giant leap forward with Policy 70, setting a new standard for transparency in the medical field. Our blog breaks down everything you need to know about this groundbreaking policy. From enhancing public health to meeting the growing demand for trust in the pharmaceutical and regulatory landscape, we've got you covered. Read more ⬇️ #emapolicy70 #transparency #healthcareinnovation

We all want trust in the medicines we take to improve ours and our families' health. This was huge motivator in the European Medicines Agency's (EMA) giant leap forward with Policy 70, setting a new standard for transparency in the medical field. Our blog breaks down everything you need to know about this groundbreaking policy. From enhancing public health to meeting the growing demand for trust in the pharmaceutical and regulatory landscape, we've got you covered. Read more ⬇️ #emapolicy70 #transparency #healthcareinnovation

GenInvo Case Study: How a Big Pharma Company Achieved Compliance with Health Canada Under Tight Deadlines . https://lnkd.in/djPqQVMH . #BigPharma #Compliance #HealthCanada #PharmaSuccess #RegulatoryCompliance #PharmaIndustry #Healthcare #PharmaRegulations #HealthCompliance #Pharmaceuticals #DeadlineSuccess #PharmaAchievements #HealthRegulations #PharmaCompliance #HealthcareStandards #PharmaInnovation #GenInvo

We all want trust in the medicines we take to improve ours and our families' health. This was huge motivator in the European Medicines Agency's (EMA) giant leap forward with Policy 70, setting a new standard for transparency in the medical field. Our blog breaks down everything you need to know about this groundbreaking policy. From enhancing public health to meeting the growing demand for trust in the pharmaceutical and regulatory landscape, we've got you covered. Read more ⬇️ #emapolicy70 #transparency #healthcareinnovation